{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:59:58Z","timestamp":1773255598502,"version":"3.50.1"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nObjectives<\/jats:title>\nTo compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI\/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-life setting.<\/jats:p>\n<\/jats:sec>\n\nMethods<\/jats:title>\nUsing logistic regression, virologic and immunologic outcomes of INSTI use were compared to outcomes of PI\/b or NNRTI treatment 12 months after treatment start or switch, for participants in the RESPOND cohort consortium. A composite treatment outcome (cTO) was used, defining success as viral load (VL) <200 copies\/mL and failure as at least one of: VL \u2265200 copies\/mL, unknown VL in the time window, any changes of antiretroviral therapy (ART) regimen, AIDS, or death. In addition, on-treatment analysis including only individuals with known VL and no regimen changes was performed. Favorable immunologic response was defined as a 25% increase in CD4 count or as reaching \u2265750 CD4 cells\/\u03bcL.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nBetween January 2012 and January 2019, 13,703 (33.0% ART-na\u00efve) individuals were included, of whom 7,147 started\/switched to a regimen with an INSTI, 3,102 to a PI\/b and 3,454 to an NNRTI-containing regimen. The main reason for cTO failure in all treatment groups were changes in ART regimen. Compared to INSTIs, the adjusted odds ratio (aOR) of cTO success was significantly lower for PI\/b (0.74 [95% confidence interval, CI 0.67\u20130.82], p <0.001), but similar for NNRTIs (1.07 [CI 0.97\u20131.17], p = 0.11). On-treatment analysis and sensitivity analyses using a VL cut-off of 50 copies\/mL were consistent. Compared to INSTIs, the aORs of a 25% increase in CD4 count were lower for NNRTIs (0.80 [CI 0.71\u20130.91], p<0.001) and PI\/b (0.87 [CI 0.76\u20130.99], p = 0.04).<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nIn this large analysis of a real-world population, cTO and on-treatment success were similar between INSTIs and NNRTIs, but lower for PI\/b, though residual confounding cannot be fully excluded. Obtaining favorable immunologic outcomes were more likely for INSTIs than the other drug classes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0243625","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T19:30:23Z","timestamp":1609443023000},"page":"e0243625","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0215-0144","authenticated-orcid":true,"given":"Bastian","family":"Neesgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Mocroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zangerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinand","family":"Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coca","family":"Necsoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella d\u2019Arminio","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pradier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikoloz","family":"Chkhartisvilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Reyes-Uruena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg Janne","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Christian","family":"Wasmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"S\u00f6nnerborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Llibre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Volny-Anne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annegret","family":"Pelchen-Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vani","family":"Vannappagari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Youle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengiz","family":"Tsertsvadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Ryom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for The RESPOND study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"issue":"9936","key":"pone.0243625.ref001","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"B Clotet","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"pone.0243625.ref002","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3018(15)00027-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study","volume":"2","author":"JM Molina","year":"2015","journal-title":"Lancet HIV"},{"issue":"1","key":"pone.0243625.ref003","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"JM Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"9835","key":"pone.0243625.ref004","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"PE Sax","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"pone.0243625.ref005","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"SL Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0243625.ref006","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"M Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"pone.0243625.ref007","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","article-title":"Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study","volume":"4","author":"C Orrell","year":"2017","journal-title":"Lancet HIV"},{"key":"pone.0243625.ref008","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services, 2018 http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf."},{"key":"pone.0243625.ref009","unstructured":"European AIDS Clinical Society Guidelines, version 10.0, November 2019."},{"key":"pone.0243625.ref010","unstructured":"BHIVA. BHIVA guidelines for the treatment of HIV positive adults with ART 2015 (2016 interim update)."},{"issue":"4","key":"pone.0243625.ref011","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel","volume":"320","author":"MS Saag","year":"2018","journal-title":"JAMA"},{"key":"pone.0243625.ref012","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2nd edtion. 2016. https:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/."},{"issue":"8","key":"pone.0243625.ref013","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8081164","article-title":"How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium","volume":"8","author":"The Respond Study Group","year":"2020","journal-title":"Microorganisms"},{"key":"pone.0243625.ref014","unstructured":"RESPOND Electronic Submission Tool (REST) User guide, 1.0, 2017 https:\/\/chip.dk\/Portals\/0\/files\/RESPOND\/RESPOND_EuroSIDA_D45_Electronic_Submission_Tool_User_guide_Version1.pdf?ver=2017-12-07-091717-467."},{"issue":"7","key":"pone.0243625.ref015","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/cid\/cit423","article-title":"The incidence of AIDS-defining illnesses at a current CD4 count \u2265200 cells\/mL in the post-combination antiretroviral therapy era","volume":"57","author":"A Mocroft","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0243625.ref016","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","author":"AN Phillips","year":"2019","journal-title":"Lancet HIV"},{"key":"pone.0243625.ref017","article-title":"Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings","author":"RM Nance","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0243625.ref018","unstructured":"Meireles VM, Pati Pascom AR, Benzaken A. CD4+ Recovery After ART Initiation: A Comparison Between Dolutegravir and Efavirenz. Conference on Retroviruses and Opportunistic Infections Seattle2019."},{"key":"pone.0243625.ref019","article-title":"Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of Dolutegravir","author":"MV Meireles","year":"2019","journal-title":"AIDS"},{"issue":"3","key":"pone.0243625.ref020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/QAI.0000000000002250","article-title":"Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting","volume":"83","author":"L Greenberg","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"13","key":"pone.0243625.ref021","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","article-title":"Adverse events of raltegravir and dolutegravir","volume":"31","author":"L Elzi","year":"2017","journal-title":"AIDS"},{"issue":"1","key":"pone.0243625.ref022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","article-title":"Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients","volume":"18","author":"C Hoffmann","year":"2017","journal-title":"HIV Med"},{"issue":"1","key":"pone.0243625.ref023","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","article-title":"Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naive patients infected with HIV-1: a systematic review and network meta-analysis","volume":"19","author":"SJ Snedecor","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"5","key":"pone.0243625.ref024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.08.008","article-title":"Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors","volume":"54","author":"LL Yang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0243625.ref025","unstructured":"Standard Operating Procedure for data transfer in RESPOND, EuroSIDA and CARE, version 3, 2019 https:\/\/chip.dk\/Portals\/0\/files\/RESPOND\/RESPOND_EuroSIDA_D45_SOP_Electronic_Version1.pdf?ver=2017-12-07-091723-823×tamp=1512634977118."},{"key":"pone.0243625.ref026","article-title":"Treatment outcomes of integrase inhibitors boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naive persons starting treatment","author":"The RESPOND Study group","year":"2020","journal-title":"HIV Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T19:30:44Z","timestamp":1609443044000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0243625"}},"subtitle":[],"editor":[{"given":"Karen","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0243625","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}